Showing results (51-60 of 396) with videos related to
Sort By:
Pageof 40
British Journal of Cancer|January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitorsRussell W Jenkins, David A Barbie, Keith T FlahertyCurrent Opinion in Oncology|April 20, 2010
Mutation-driven drug development in melanomaKeith T Flaherty, F Stephen Hodi, Boris C BastianCurrent Opinion in Oncology|February 28, 2008
The MAPK pathway in melanomaLeslie A Fecher, Ravi K Amaravadi, Keith T FlahertyNature Reviews. Cancer|October 13, 2020
Author Correction: From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E FisherClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will beRyan J Sullivan, Patricia M Lorusso, Keith T FlahertyAmerican Journal of Clinical Oncology|April 2, 2004
Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancerKeith T Flaherty, S Bruce Malkowicz, David J VaughnCancer Discovery|November 15, 2014
Universes collide: combining immunotherapy with targeted therapy for cancerJennifer A Wargo, Zachary A Cooper, Keith T FlahertyAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
New options and new questions: how to select and sequence therapies for patients with metastatic melanomaKeith T Flaherty, Jeff A Sosman, Michael B AtkinsCancer Research|April 9, 2009
Genetic subgrouping of melanoma reveals new opportunities for targeted therapyKeiran S M Smalley, Katherine L Nathanson, Keith T FlahertyJournal of the National Cancer Institute|April 10, 2016
The Conundrum of Genetic "Drivers" in Benign ConditionsShumei Kato, Scott M Lippman, Keith T Flaherty, et al.Pageof 40